Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has shown that PV is associated with a lower quality of life in measures, ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...

Polycythemia vera (PV) is a slow-growing blood cancer in which your body makes too many red blood cells. You may have it for years before you notice any symptoms. Most people find out they have PV ...

Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.